Apeiron RIA LLC Sells 410 Shares of Medtronic PLC $MDT

Apeiron RIA LLC decreased its position in Medtronic PLC (NYSE:MDT) by 11.0% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,314 shares of the medical technology company’s stock after selling 410 shares during the quarter. Apeiron RIA LLC’s holdings in Medtronic were worth $298,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Burkett Financial Services LLC lifted its holdings in Medtronic by 185.0% in the first quarter. Burkett Financial Services LLC now owns 285 shares of the medical technology company’s stock valued at $26,000 after acquiring an additional 185 shares during the period. 1248 Management LLC bought a new position in shares of Medtronic in the first quarter worth about $26,000. Wood Tarver Financial Group LLC bought a new position in shares of Medtronic in the fourth quarter worth about $27,000. Columbia River Financial Group LLC bought a new position in shares of Medtronic in the first quarter worth about $28,000. Finally, Twin Tree Management LP bought a new position in shares of Medtronic in the first quarter worth about $29,000. Institutional investors own 82.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Leerink Partners assumed coverage on Medtronic in a research note on Monday, June 16th. They issued an “outperform” rating and a $110.00 price objective on the stock. Citigroup raised their price objective on Medtronic from $99.00 to $101.00 and gave the stock a “buy” rating in a research note on Thursday, August 21st. Needham & Company LLC reaffirmed a “hold” rating on shares of Medtronic in a research note on Thursday, August 14th. Argus raised their price objective on Medtronic from $105.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday, August 26th. Finally, Leerink Partnrs raised Medtronic to a “strong-buy” rating in a research note on Monday, June 16th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $102.14.

Medtronic Stock Performance

NYSE:MDT opened at $94.13 on Friday. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $96.25. The stock has a 50-day moving average price of $91.39 and a 200 day moving average price of $88.26. The stock has a market capitalization of $120.74 billion, a P/E ratio of 25.93, a P/E/G ratio of 2.43 and a beta of 0.77.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The firm had revenue of $8.58 billion during the quarter, compared to analysts’ expectations of $8.37 billion. During the same quarter last year, the business posted $1.23 earnings per share. The firm’s revenue was up 7.7% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Equities research analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 17th. Shareholders of record on Friday, September 26th will be issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.0%. The ex-dividend date is Friday, September 26th. Medtronic’s dividend payout ratio (DPR) is currently 78.24%.

Insider Activity at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the firm’s stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the completion of the transaction, the executive vice president owned 35,615 shares in the company, valued at $3,261,621.70. This trade represents a 19.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director William R. Jellison purchased 2,500 shares of the business’s stock in a transaction on Monday, August 25th. The shares were purchased at an average price of $92.37 per share, with a total value of $230,925.00. Following the acquisition, the director directly owned 5,000 shares in the company, valued at $461,850. This represents a 100.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.